Home > Publications database > Integrated genomic analysis reveals actionable targets in pediatric spinal cord low-grade gliomas. > print

001     181956
005     20240917162237.0
024 7 _ |a 10.1186/s40478-022-01446-0
|2 doi
024 7 _ |a pmid:36163281
|2 pmid
024 7 _ |a pmc:PMC9513869
|2 pmc
024 7 _ |a altmetric:136487046
|2 altmetric
037 _ _ |a DKFZ-2022-02326
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Misove, Adela
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Integrated genomic analysis reveals actionable targets in pediatric spinal cord low-grade gliomas.
260 _ _ |a London
|c 2022
|b Biomed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1726582938_15212
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Gliomas are the most common central nervous tumors in children and adolescents. However, spinal cord low-grade gliomas (sLGGs) are rare, with scarce information on tumor genomics and epigenomics. To define the molecular landscape of sLGGs, we integrated clinical data, histology, and multi-level genetic and epigenetic analyses on a consecutive cohort of 26 pediatric patients. Driver molecular alteration was found in 92% of patients (24/26). A novel variant of KIAA1549:BRAF fusion (ex10:ex9) was identified using RNA-seq in four cases. Importantly, only one-third of oncogenic drivers could be revealed using standard diagnostic methods, and two-thirds of pediatric patients with sLGGs required extensive molecular examination. The majority (23/24) of detected alterations were potentially druggable targets. Four patients in our cohort received targeted therapy with MEK or NTRK inhibitors. Three of those exhibited clinical improvement (two with trametinib, one with larotrectinib), and two patients achieved partial response. Methylation profiling was implemented to further refine the diagnosis and revealed intertumoral heterogeneity in sLGGs. Although 55% of tumors clustered with pilocytic astrocytoma, other rare entities were identified in this patient population. In particular, diffuse leptomeningeal glioneuronal tumors (n = 3) and high-grade astrocytoma with piloid features (n = 1) and pleomorphic xanthoastrocytoma (n = 1) were present. A proportion of tumors (14%) had no match with the current version of the classifier. Complex molecular genetic sLGGs characterization was invaluable to refine diagnosis, which has proven to be essential in such a rare tumor entity. Moreover, identifying a high proportion of drugable targets in sLGGs opened an opportunity for new treatment modalities.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a KIAA1549:BRAF fusion
|2 Other
650 _ 7 |a Low-grade glioma
|2 Other
650 _ 7 |a Methylation profiling
|2 Other
650 _ 7 |a NTRK fusion
|2 Other
650 _ 7 |a Spinal cord
|2 Other
650 _ 7 |a Proto-Oncogene Proteins B-raf
|0 EC 2.7.11.1
|2 NLM Chemicals
650 _ 7 |a Mitogen-Activated Protein Kinase Kinases
|0 EC 2.7.12.2
|2 NLM Chemicals
650 _ 2 |a Adolescent
|2 MeSH
650 _ 2 |a Astrocytoma: genetics
|2 MeSH
650 _ 2 |a Brain Neoplasms: genetics
|2 MeSH
650 _ 2 |a Child
|2 MeSH
650 _ 2 |a Genomics
|2 MeSH
650 _ 2 |a Glioma: genetics
|2 MeSH
650 _ 2 |a Glioma: pathology
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Mitogen-Activated Protein Kinase Kinases
|2 MeSH
650 _ 2 |a Proto-Oncogene Proteins B-raf: genetics
|2 MeSH
650 _ 2 |a Spinal Cord Neoplasms: genetics
|2 MeSH
700 1 _ |a Vicha, Ales
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Broz, Petr
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Vanova, Katerina
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Sumerauer, David
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Stolova, Lucie
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Sramkova, Lucie
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Koblizek, Miroslav
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Zamecnik, Josef
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Kyncl, Martin
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Holubova, Zuzana
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Liby, Petr
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Taborsky, Jakub
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Benes, Vladimir
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Pernikova, Ivana
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 15
|u dkfz
700 1 _ |a Sill, Martin
|0 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
|b 16
|u dkfz
700 1 _ |a Stancokova, Terezia
|0 P:(DE-HGF)0
|b 17
700 1 _ |a Krskova, Lenka
|0 P:(DE-HGF)0
|b 18
700 1 _ |a Zapotocky, Michal
|0 P:(DE-HGF)0
|b 19
773 _ _ |a 10.1186/s40478-022-01446-0
|g Vol. 10, no. 1, p. 143
|0 PERI:(DE-600)2715589-4
|n 1
|p 143
|t Acta Neuropathologica Communications
|v 10
|y 2022
|x 2051-5960
909 C O |p VDB
|o oai:inrepo02.dkfz.de:181956
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-01-28
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-01-28
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA NEUROPATHOL COM : 2021
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-02-14T16:20:11Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-02-14T16:20:11Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-02-14T16:20:11Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-09
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-09
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ACTA NEUROPATHOL COM : 2021
|d 2022-11-09
920 1 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pädiatrische Gliomforschung
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B360-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21